Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.
Nanotechnology is a rapidly emerging drug-delivery system that makes possible the controlled release of small molecules, and nanodelivery of therapeutic molecules using nanoparticles or nanogels represents a major improvement for more focused delivery of such therapeutic molecules. The delivery of insulin for the control of diabetes mellitus (DM) and aldose reductase inhibitor (ARI) for diabetic complications may provide better treatment of diabetes. A structural overview of aldose reductase including computational docking experiments with HAR-1, various ARIs, aldose-keto reductase, and nanodelivery of insulin, ARI's, and drug molecules are described.
Department of Chemistry, 213 CBC Building, Kansas State University, Manhattan, KS 66506, USA.
A M
AM
Prior
M
M
Thapa
D H
DH
Hua
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004337:Drug Carriers / Q000737:chemistry*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D049329:Nanostructures / Q000737:chemistry*
D004337:Drug Carriers; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D000449:Aldehyde Reductase